SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT04287179 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled.

Conditions

Interventions

Sponsor

Novo Nordisk A/S